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Abstract
Background: There is still no worldwide agreement on the best diagnostic thresholds to define gestational
diabetes (GDM) or the optimal approach for identifying women with GDM. Should all pregnant women perform an
oral glucose tolerance test (OGTT) or can easily available maternal characteristics, such as age, BMI and ethnicity,
indicate which women to test? The aim of this study was to assess the prevalence of GDM by three diagnostic
criteria and the predictive accuracy of commonly used risk factors.
Methods: We merged data from four Norwegian cohorts (2002–2013), encompassing 2981 women with complete
results from a universally offered OGTT. Prevalences were estimated based on the following diagnostic criteria:
1999WHO (fasting plasma glucose (FPG) ≥7.0 or 2-h glucose ≥7.8 mmol/L), 2013WHO (FPG ≥5.1 or 2-h glucose ≥8.5
mmol/L), and 2017Norwegian (FPG ≥5.3 or 2-h glucose ≥9 mmol/L). Multiple logistic regression models examined
associations between GDM and maternal factors. We applied the 2013WHO and 2017Norwegian criteria to evaluate
the performance of different thresholds of age and BMI.
Results: The prevalence of GDM was 10.7, 16.9 and 10.3%, applying the 1999WHO, 2013WHO, and the 2017Norwegian
criteria, respectively, but was higher for women with non-European background when compared to European
women (14.5 vs 10.2%, 37.7 vs 13.8% and 27.0 vs 7.8%). While advancing age and elevated BMI increased the risk of
GDM, no risk factors, isolated or in combination, could identify more than 80% of women with GDM by the latter
two diagnostic criteria, unless at least 70–80% of women were offered an OGTT. Using the 2017Norwegian criteria,
the combination “age≥25 years or BMI≥25 kg/m2” achieved the highest sensitivity (96.5%) with an OGTT required
for 93% of European women. The predictive accuracy of risk factors for identifying GDM was even lower for non-
European women.
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Conclusions: The prevalence of GDM was similar using the 1999WHO and 2017Norwegian criteria, but substantially
higher with the 2013WHO criteria, in particular for ethnic non-European women. Using clinical risk factors such as
age and BMI is a poor pre-diagnostic screening method, as this approach failed to identify a substantial proportion
of women with GDM unless at least 70–80% were tested.
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Background
Gestational diabetes mellitus (GDM) is glucose in-
tolerance with onset or first diagnosis during preg-
nancy which is clearly not overt diabetes [1]. GDM is
associated with higher maternal and neonatal morbid-
ities in the short- and long-term and predisposes both
women and their offspring to later development of
type 2 diabetes [2]. Screening followed by treatment
of GDM reduces the risk of several pregnancy com-
plications [3]. However, there is no worldwide agree-
ment on the best diagnostic thresholds to define
GDM, and a wide variety of clinical guidelines have
been employed [4].
In 2013, the World Health Organization (WHO)
recommended glycaemic thresholds for the diagnosis
of GDM based on findings from the multinational
Hyperglycaemia and Adverse Pregnancy Outcome
(HAPO) study demonstrating a linear dose-response
between maternal glycaemia and adverse neonatal
outcomes. These criteria were determined to identify
women with an adjusted odds ratio (OR) of 1.75 for
adverse events in their offspring relative to the mean
[5]. Glucose values set to identify women with a
higher risk, corresponding to an adjusted OR of 2.0,
were also considered but this proposal was rejected.
Nonetheless, several countries, among them Canada
and Norway, adopted the latter noting the substantial
rise in GDM prevalence by 2013WHO criteria, without
clear evidence of clinically important benefits [6]. The
prior WHO criteria, established in 1999 and used in
Norway until 2017, were identical to those for diag-
nosis of glucose intolerance in a non-pregnant
population.
Controversy surrounds not only the thresholds
values of glycemia, but also the optimal approach for
identifying women with GDM. A high-risk approach
has traditionally been recommended based on easily
available maternal characteristics such as advanced
age and BMI, known to be associated with an in-
creased risk of GDM [7]. However, although this ap-
proach reduces unnecessary testing in those least
likely to test positive, a key issue is their perform-
ance as indicators for diagnostic testing and the use-
fulness of risk factors in a clinical setting today [8].
The alternative option, universal screening, has a
high detection rate but poses a large immediate
burden to healthcare services as well as pregnant
women.
In this study that merged data from four existing
Norwegian pregnancy and birth cohorts, we aimed to
address some of the clinical controversies related to
GDM diagnosis and screening. The objectives were:
1) To establish the prevalence of GDM with three
diagnostic criteria (1999WHO, 2013WHO, and the
2017Norwegian criteria), 2) identify cut-off levels for
age and BMI that identify at least 80% of women with
GDM and 3) assess the predictive accuracy of com-
monly used risk factors.
Methods
All population-based birth cohort studies in Norway
with a special focus on gestational diabetes were eli-
gible. For the present study, the following inclusion
criteria were defined: (i) prospective studies compris-
ing women with singleton live-born children recruited
early in pregnancy (between week 15–20); (ii) data on
maternal pre-pregnancy BMI; (iii) glucose measure-
ments obtained from at least one universally offered
75 g 2-h oral glucose tolerance test (OGTT) per-
formed ≥20 weeks’ gestation; (iv) at least one offspring
measurement (birthweight). Exclusion criteria were
studies without the core data and studies that only
included specific subgroups (such as obese women
only).
Four Norwegian studies (two cohort studies ( [9,
10] and two randomized controlled trials (RCT) [11,
12] were identified, and primary investigators were in-
vited to become part of the “Norwegian Hypergly-
cemia in pregnancy” consortium in 2017. Principal
investigators from all four studies agreed to partici-
pate, providing data from 3315 pregnant women and
3293 live births (Fig. 1).
The original studies collected data between 2002
and 2013. If GDM was diagnosed, women received
diabetes care according to local guidelines. Details of
the methods and characteristics of participants in
each study, including eligibility criteria, methods of
recruitment and measurements obtained, have been
previously published [9–12]. Authors were requested
to provide anonymous raw data to be stored and an-
alyzed in The University of Oslo’s Service for Sensi-
tive data (TSD) storage platform with access for all
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the project partners. Data were further harmonized
and assessed for internal consistency and missing
items. Investigators were asked for clarification on
issues regarding the coding of variables and a final
summary of relevant variables was sent for verifica-
tion. After resolution, all datasets were merged. We
excluded from analyses participants for which no
OGTT data were available, as well as multi-fetal
pregnancies (Fig. 1).
The primary outcome was GDM prevalence. All
women underwent a 75 g OGTT after an overnight fast.
In two of the studies [9, 10] venous blood samples were
collected in tubes containing Ethylenediaminetetraacetic
acid (EDTA) and glucose was analyzed on site in fresh,
whole EDTA blood, using HemoCue 201+ glucose ana-
lyser (Angelholm, Sweden) [9] or a Accu-Chek Sensor
glucometer (Roche Diagnostics, Mannheim, Germany)
[10] according to protocols. In Sagedal et al. [11] and
Stafne et al. [12] fasting and 2-h glucose levels were
measured in plasma or serum, respectively, by the rou-
tine methods used at the participating hospital
laboratory.
The diagnosis was originally made according to the
1999WHO criteria which was used during data collection.
In addition, we applied the 2013WHO criteria and the
2017Norwegian criteria (Table 1) for the purposes of this
specific study. The 2013WHO criteria also includes a 1-h
glucose which was not measured in the respective
studies.
In each individual study, women were either inter-
viewed or asked to complete a questionnaire including
information on current smoking status and their highest
educational qualification. Women were further assessed
at the study sites with respect to biological and an-
thropometric data. Height was measured directly while
weight prior to becoming pregnant was self-reported in
all studies. Categories for age and pre-pregnancy body
mass index (BMI) were determined prior to analysis and
based on clinical relevance. Furthermore, women were
classified as primiparous or parous for the purpose of
this study.
STORK Groruddalen [9] was the only study that ac-
tively included a multiethnic population (59% ethnic
minority women, primarily born outside Europe). Eth-
nic origin was defined as European (predominantly
Scandinavian as well as East and West-European ori-
gin) or non-European (mainly Asian, North-African,
Middle Eastern or Sub-Sahara African). Family history
of diabetes was not measured in the Fit for Delivery
study.
Statistical analysis
Distributions of all potential predictors were checked
for normality. The characteristics of the women were
categorized by GDM-status and the two groups were
compared using X2 statistic for categorical data and
the Student’s t Test for continuous variables. Data are
reported as frequencies and percentages for categor-
ical variables and mean and standard deviation for
continuous variables.
Information was available for 95% of the selected
covariates. To assign values for the missing data for
Fig. 1 Flowchart of included studies and excluded participants from each study
Table 1 Criteria for gestational diabetes
Glucose value 1999WHO 2013WHO 2017Norwegian
Fasting ≥7.0 mmol/L ≥5.1 mmol/L ≥5.3 mmol/L
2-h ≥ 7.8 mmol/L ≥8.5 mmol/L ≥9.0 mmol/L
Based on a 75 g Oral Glucose Load. For the diagnosis, one or more of the
glucose values must be met or exceeded
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pre-pregnancy weight (5%), height (0.4%), educational
attainment (0.3%) and parity (0.3%) we used Stochas-
tic regression imputation with predictive mean match-
ing as the imputation model to substitute missing
items in the observed population [13].
To examine associations between GDM and maternal
factors, we modelled GDM as a binary outcome (GDM
vs no-GDM) and variables related to GDM in univari-
able logistic regression models with p-value < 0.2 were
considered in separate multivariable analyses [14]. The
final model resulted from a backward selection proced-
ure (exclusion if p > 0.15). All models were adjusted for
cohort to handle unmeasured confounders. Results from
logistic regression are presented as OR with accompan-
ied 95% confidence intervals (CI), and with Nagelkerke
R2 for model fit.
In the analyses, the two RCT’s were treated as co-
hort studies as the primary outcome (GDM) did not
differ between control and intervention group in the
original studies [11, 12]. The interventions in the
two trials consisted of either an exercise program
(supervised exercise sessions) or a combination of a
physical activity component and dietary counselling.
The regression analysis was repeated after excluding
participants who received the intervention to exam-
ine the potential role of the intervention in these
RCTs.
Finally, we assessed the diagnostic accuracy across
different pre-specified cut-offs for maternal age and
BMI with and without the addition of parity, based
on previous and current screening guidelines. We
calculated sensitivity (proportion of GDM cases cor-
rectly identified by the risk factor), specificity (pro-
portion of women without GDM who did not have
the risk factor), and the proportion of women with
the risk factor (i.e. who would be offered an OGTT).
Analyses were performed and presented separately
for European and non-European women due to
strong effect of ethnicity. For each risk factor, single
or in combination, the sensitivity estimates were
plotted in Receiver Operating Characteristic (ROC)
space against the proportion of women subjected to
OGTT. An optimal risk factor combination will have
high sensitivity with small numbers needing to be
tested (results near the top left of the space). We
opted for a sensitivity level of 80% for the risk fac-
tors. Statistical analyses were performed using SPSS
software, Version 26 (USA).
Results
We excluded more participants from the TRIP study
than from the other studies due to missing GDM
data (Fig. 1). Apart from this, no significant differ-
ences were noted between the women who were
included in the study and those excluded (not
shown). After exclusions, the pooled dataset com-
prised 2981 women with a mean (SD) age of 30.2
(4.4) years and pre-pregnant BMI of 23.7 kg/m2
(Table 2). The majority were of European origin
(87.0%), had higher education (73.4%) and were in
their first pregnancy (61.0%). GDM was diagnosed in
320 (10.7%), 504 (16.9%) and 308 (10.3%) pregnan-
cies with the 1999WHO, 2013WHO and 2017Norwegian
criteria, respectively.
The prevalence rates in European women com-
pared to non-European women were 10.2 vs 14.5%,
13.8 vs 37.7% and 7.8 vs 27.0%, applying the
1999WHO, 2013WHO and 2017Norwegian criteria, re-
spectively (Fig. 2).
Compared with the non-GDM group, women diag-
nosed with GDM by either criteria were more likely
to be older, heavier, shorter and of non-European
origin (Supporting information Table S1, add-
itional file 1). Moreover, using the 2017Norwegian
criteria, while 25.5% of women without GDM had
overweight or obesity (BMI > 25 kg/m2), this was ob-
served in 51.3% of women with GDM (P < 0.001).
There were more primiparas in the non-GDM group
(P < 0.001), except when applying the 1999WHO
criteria.
In logistic regression analyses, all selected variables
except smoking, were significantly associated with
GDM with the 2017Norwegian criteria prior to ad-
justments (Table 3). Nevertheless, the associations
observed for parity, education and height were
strongly attenuated and lost their significance in the
multivariable adjusted model 1. Age, pre-pregnancy
BMI and ethnicity remained the only significant pre-
dictors in the final multivariable model (model 2).
However, compared with women ≤25 years, an in-
creased OR for developing GDM was only found for
those above 35 years of age (aOR 1.73; 95% CI:
1.07–2.80; P < 0.026).
Applying the 2013WHO criteria led to similar find-
ings (Table 4). For the 1999WHO, however, non-
European ethnicity was not significantly associated
with GDM, while parity and height remained signifi-
cant in the final adjusted model (Supporting infor-
mation Table S2, additional file 1). The predictive
power of all models was low, with Nagelkerke values
ranging from 0.9 to 16.4%, depending on the criteria
applied. Sensitivity analysis restricted to individuals
without lifestyle intervention in two of the cohorts
led to similar findings, although age was no longer
significant (not shown).
Table 5 displays estimates of sensitivity and the
proportion needed to be screened for selected risk
factors combinations, stratified for ethnic origin. In
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European women, the combination “age≥25 years or
BMI≥25 kg/m2” achieved the highest sensitivity of
96.5% (i.e. detected 96.5% of GDM cases), but be-
cause these risk factors occurred in 93%, an OGTT
would be required in almost all women. By adding
parity to the age thresholds (25 years for primipara
and 35 years for parous) the number of OGTT
needed was reduced to 75%, although a reduction in
sensitivity to 85% was observed. Similar trends were
observed for women with non-European background,
except that family history of diabetes achieved a
higher sensitivity (42.6%) than in their European
counterparts (11%). Overall, the sensitivity of the risk
factors was slightly higher when applying the
2017Norwegian criteria than the 2013WHO.
Figure 3 shows the proportion of correctly identi-
fied GDM cases for European women, and propor-
tion that would be offered an OGTT for each risk
factor or combination of factors by the
2017Norwegian and 2013WHO criteria. Irrespective of
the risk factor used, the sensitivity increased with
the number of women needing a test for both diag-
nostic criteria, displaying three clusters of four to
five factors with poor, moderate and good perform-
ance. To identify at least 80% of women with GDM
(good performance), at least 75% of all women
would need to undergo an OGTT. The risk factor
displaying both high sensitivity and the smallest pro-
portion of OGTT’s, was the combination “BMI≥25
kg/m2 or (primipara+age≥25) or (parous+age≥35)”.
With 75% requiring a test, this factor combination
failed to identify 15% of women with GDM by
2017Norwegian criteria. The proportion of OGTT re-
quired could be reduced to 54% by increasing the
threshold for age to ≥30 years for primipara (moder-
ate performance); however, this approach implies
that 27% of women with GDM will remain undiag-
nosed (Table 5).
Table 2 Characteristics of the participating pregnancy and birth cohorts
Characteristics Stork Grorudddalen Stork Rikshospitalet Fit for Delivery TRIP Total
n = 752 n = 983 n = 545 n = 701 n = 2981
Study period 2008–2010 2002–2008 2009–2013 2007–2009
Type of study cohort cohort RCT RCT
Gest. age at inclusion (weeks) 15.1 ± 3.4 15.8 ± 1.3 15.1 ± 2.6 20.2 ± 1.6 16.5 ± 3.1
Gest. age at OGTT (weeks) 28.3 ± 1.3 31.2 ± 1.0 29.6 ± 0.8 34.0 ± 2.0 30.8 ± 2.5
European ethnicity 363 (48.3) 983 (100) 541 (99.3) 701 (100) 2588 (86.8)
Current smoker 31 (5.0) 23 (2.3) 20 (3.7) 6 (0.9) 80 (2.8)
Education
primary or less 124 (16.5) 12 (1.2) 10 (1.8) 3 (0.4) 149 (5.0)
High school education 297 (39.5) 128 (13.0) 158 (29.0) 62 (8.8) 645 (21.6)
Higher education 331 (44.0) 843 (85.8) 377 (69.2) 636 (90.7) 2187 (73.4)
Primipara 345 (45.9) 524 (53.3) 545 (100) 405 (57.8) 1819 (61.0)
Diabetes in family 191 (26.1) 98 (10.5) NM 61 (9.1) 350 (11.7)
Age (years)
Total 29.9 ± 4.8 31.3 ± 3.8 28.0 ± 4.3 30.6 ± 4.2 30.2 ± 4.4
Primipara 28.1 ± 4.6 30.0 ± 3.7 28.0 ± 4.3 29.2 ± 3.7 28.9 ± 4.1
Parous 31.4 ± 4.5 32.7 ± 3.6 a 32.4 ± 4.1 32.2 ± 4.0
Prepregnant BMI (kg/m2) 24.6 ± 4.8 23.4 ± 3.7 23.6 ± 3.8 23.1 ± 3.1 23.7 ± 3.9
BMI at inclusion (kg/m2) 25.3 ± 4.8 24.5 ± 3.4 24.5 ± 3.9 24.7 ± 3.1 24.8 ± 4.0
Fasting glucose at OGTT (mmol/L) 4.8 ± 0.6 4.6 ± 0.4 4.6 ± 0.4 4.3 ± 0.4 4.6 ± 0.5
2-h glucose at OGTT (mmol/L) 6.2 ± 1.4 6.2 ± 1.4 6.1 ± 1.3 5.7 ± 1.2 6.1 ± 1.3
GDM, 1999WHO-criteria 97 (12.9) 124 (12.6) 57 (10.5) 42 (6.0) 320 (10.7)
GDM, 2013WHO-criteria 236 (31.4) 145 (14.8) 76 (13.9) 47 (6.7) 504 (16.9)
GDM, 2017Norway-criteria 156 (20.7) 87 (8.9) 38 (7.0) 27 (3.9) 308 (10.3)
Data presented as mean ± SD or n (%). Values are imputed for pre-pregnancy weight, parity and education
a Only primipara included in the study
OGTT oral glucose tolerance test, BMI body mass index, GDM gestational diabetes mellitus, WHO World Health Organization, NM not measured
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Discussion
In this study of women universally offered an OGTT
during the second half of pregnancy, we found a
similar overall prevalence of GDM (10.7% vs 10.3%)
with the 2017Norwegian criteria and the previously
used criteria (1999WHO), but using lower glucose
level thresholds in line with 2013WHO criteria, iden-
tified considerably higher numbers of women with
GDM (16.9%). The prevalence more than doubled
for non-European women applying the 2013WHO and
2017Norwegian criteria, even after adjusting for co-
variates. Our study further shows that while advan-
cing age and elevated BMI increased the risk of
GDM, using these risk factors in pre-diagnostic
screening is a poor method for accurately identifying
women with GDM, resulting in many missed cases
unless 70–80% of European women are tested. The
sensitivity of the risk factors was lower for non-
European women, indicating an even stronger ration-
ale for universal screening in these women.
Although shifting from the older 1999WHO criteria
to the new 2017Norwegian criteria resulted in a simi-
lar frequency of GDM, the groups identified differ
in terms of their metabolic profile. The latter
criteria identified more women with a higher pre-
pregnancy BMI and non-European ethnicity, pre-
sumably attributable to the lower fasting glucose
threshold.
Our prevalence rates applying the 2013WHO cri-
teria are comparable with estimates reported in
other studies in the past decade, although differences
in screening procedures, demographic characteristics
of the subjects as well as the ethnic make-up of the
population make direct comparisons complex. Guari-
guata et al. [15] estimated that the global prevalence
of hyperglycaemia using the 2013WHO criteria was
16.9%. A more recent meta-analysis of high-income
countries in Europe found an overall GDM preva-
lence of 5.4%, regardless of diagnostic criteria used
[16]. In contrast, a study using 2013WHO thresholds
and only fasting glucose in a Danish pregnancy co-
hort, found that 40% were classified as having GDM
[17]. The authors raised important questions about
uniform application of diagnostic thresholds across
the world, and suggested population-based local
recommendations.
Multiple studies have evaluated selective risk
factor-based strategies aiming to identify the best
diagnostic approach for GDM [18, 19]. We demon-
strate that the most sensitive and specific cut-offs
for maternal age and BMI in European women were
age ≥ 25 years and BMI ≥25 kg/m2 when parity was
added. However, used as a screening strategy this
would mean inviting the majority of women for an
OGTT as at least one of these risk factors applies to
most women today. This confirms recent findings
from a systematic review and meta-analysis by Farrar
et al. [8] concluding that sensitivity increases with
the number of women needing a test. This strategy
does not vary much from universal screening, and
supports the contention that identification of GDM
requires testing of almost all pregnant women [20]
Fig. 2 GDM prevalence based on three diagnostic criteria (2017Norwegian, 2013WHO, 1999WHO) for European and non-European women
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especially considering the rise in maternal age and
overweight/obesity among childbearing over recent
years [21].
Selective screening has the potential to spare
many pregnant women of diagnostic testing thereby
reducing time and resource use. However, consistent
with others [22, 23] we found that screening on the
basis of risk factors would result in a larger number
of missed diagnoses and hence limit the opportunity
for immediate and long-term follow up and treat-
ment. This is of concern, as a substantial proportion
of women with GDM have no defined risk factors
[24, 25]. The importance of GDM management is
now widely accepted, and evidence supports that
treatment of even milder degrees of hyperglycaemia
could improve pregnancy outcomes [26, 27].
Additionally, universal screening has the unique po-
tential to identify this subset of women who would
not otherwise be identified as having GDM, and,
therefore, provide clinicians, as well as the women
themselves, an opportunity to plan postpartum life-
style interventions that could prevent or delay the
onset of future type 2 diabetes [28–30].
Our study has several strengths. We merged data
from four contemporary birth cohorts, allowing
more powerful and flexible analyses. Additionally,
although the level of missing was generally low,
missing data were adequately handled by multiple
imputation to prevent biased results. By including
different geographical populations in Norway, we
believe that the results may be broadly generalizable
in Norway as well as to different antenatal
Table 3 Associations between maternal risk factors and gestational diabetes mellitus in univariate analysis and multivariate analysis,
applying the 2017Norwegian criteria
Variables Univariate analysis Model 1ª: r2 = 0.158 Model 2єr2 = 0.157
Odds ratio 95% CI P-value aOR 95% CI P-value aOR 95% CI P-value
Age (years) 0.001 0.003 0.003
≤ 25 1 1 1
25–29.9 0.76 0.52–1.14 0.191 0.90 0.57–1.41 0.651 0.86 1.20–2.58 0.495
30–34.9 0.82 0.55–0.21 0.319 1.07 0.67–1.71 0.768 1.00 0.64–1.56 0.984
≥ 35 1.42 0.93–2.16 0.100 1.84 1.10–3.07 0.020 1.73 1.07–2.80 0.026
Pre-pregnancy BMI (kg/m2) < 0.001 < 0.001 < 0.001
≤ 25 1 1 1
25–26.9 1.86 1.30–2.66 0.001 1.76 1.20–2.57 0.004 1.77 1.21–2.58 0.003
27–29.9 2.73 1.89–3.95 < 0.001 2.60 1.75–3.87 < 0.001 2.64 1.78–3.92 < 0.001
≥ 30 5.97 4.31–8.26 < 0.001 4.96 3.43–7.16 < 0.001 5.12 3.56–7.35 < 0.001
non-European ethnicity 4.36 3.35–5.69 < 0.001 2.46 1.53–3.94 < 0.001 2.72 1.78–4.13 < 0.001
Parous 1.53 1.21–1.94 < 0.001 0.99 0.73–1.34 0.955
Education 0.725
Higher education 1 1
high school education 2.07 1.59–2.71 < 0.001 1.12 0.79–1.58 0.504
primary or less 4.60 3.11–6.80 < 0.001 1.21 0.69–2.09 0.509
Height (cm) 0.95 0.93–0.96 < 0.001 0.99 0.96–1.01 0.341
Current smoker 1.66 0.89–3.11 0.112 1.29 0.65–2.56 0.454
Cohort
Stork Rikshospitalet 1
FFF 0.77 0.52–1.15 0.200
STORK Groruddalen 2.70 2.03–3.57 < 0.001
TRIP 0.41 0.26–0.64 < 0.001
Diabetes in family* 1.88 1.40–2.53 < 0.001
Binary logistic regression was performed, 2017Norway criteria
aAdjusted for age, pre-pregnancy BMI, ethnicity, parity, education, height, smoking and cohort (not shown)
єAdjusted for age, pre-pregnancy BMI, ethnicity and cohort (not shown)
Abbrevations: aOR adjusted odds ratio, CI confidens interval, BMI body mass index
* Not measured in Fit for Delivery
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populations in other high-income countries. More-
over, our study included women from various ethnic
groups, making our findings relevant to other Euro-
pean countries with similar immigrant populations.
It is of note, however, that almost all non-European
women came from one study and more than half
were of Asian (mainly South Asian) origin. Never-
theless, the proportion included and the compos-
ition of this group, is representative for the
pregnant population with non-European ethnicity
living in Norway [31].
The majority of the European women in our study
had a normal BMI and high educational level, which
may indicate that our prevalence rates of GDM are
less generalizable to more high-risk populations. The
rates of overweight and obesity in our cohort were
somewhat lower than our background population
(8% obesity in our study vs 12% nationally in 2018)
[32]. A selection bias towards inclusion of individ-
uals with a higher health awareness, as is often seen
in clinical studies, may have led to underestimation
of the reported prevalence rates and the numbers
needed to be screened. A higher proportion of over-
weight/obesity would require an OGTT of a larger
number of women. In addition, had a 1-h value been
measured in our study, the prevalence of GDM by
the 2013WHO criteria would presumably have in-
creased somewhat. Second, two of the included stud-
ies were RCT’s with a lifestyle intervention for half
of the women. However, no effect of the intervention
on GDM status was reported in these studies and,
reassuringly, our findings remained unchanged in
sensitivity analyses. Lastly, we present data from four
cohorts pooled into one data set where each study
Table 4 Associations between maternal risk factors and gestational diabetes mellitus in univariate analysis and multivariate analysis,
applying the 2013WHO criteria
Variables Univariate analysis Model 1ª: r2 = 0.164 Model 2єr2 = 0.163
Odds ratio 95% CI P-value aOR 95% CI P-value aOR 95% CI P-value
Age (years) < 0.001 < 0.001 < 0.001
≤ 25 1 1 1
25–29.9 0.74 0.53–1.01 0.062 0.91 0.63–1.32 0.622 0.87 0.60–1.25 0.445
30–34.9 0.85 0.62–1.17 0.321 1.24 0.84–1.83 0.267 1.18 0.82–1.70 0.381
≥ 35 1.50 1.07–2.13 0.020 2.17 1.42–3.33 < 0.001 2.07 1.38–3.09 < 0.001
Pre-pregnancy BMI (kg/m2) < 0.001 < 0.001 < 0.001
≤ 25 1 1 1
25–26.9 1.84 1.38–2.46 < 0.001 1.69 1.24–2.30 0.001 1.70 1.25–2.32 < 0.001
27–29.9 3.23 2.40–4.35 < 0.001 2.96 2.15–4.09 < 0.001 3.02 2.18–4.16 0.001
≥ 30 4.84 3.60–6.49 < 0.001 3.90 2.80–5.43 < 0.001 4.06 2.93–5.61 < 0.001
non-European ethnicity 3.79 3.00–4.78 < 0.001 1.91 1.28–2.86 0.002 2.17 1.51–3.10 < 0.001
Parous 1.49 1.23–1.80 < 0.001 1.02 0.79–1.31 0.875
Education 0.340
Higher education 1 1
high school education 1.89 1.52–2.36 < 0.001 1.43 0.88–2.33 0.148
primary or less 4.17 2.94–5.92 < 0.001 1.11 0.84–1.47 0.474
Height 0.96 0.94–0.97 < 0.001 0.99 0.98–1.00 0.580
Current smoker 0.65 0.38–1.12 0.119 1.13 0.98–1.01 0.674
Cohort < 0.001
Stork Rikshospitalet 1
FFF 0.94 0.69–1.26 0.668
STORK G 2.64 2.09–3.34 < 0.001
TRIP 0.41 0.29–0.59 < 0.001
Diabetes in family * 1.85 1.44–2.38 < 0.001
Binary logistic regression was performed, 2013WHO-criteria.
aAdjusted for age, pre-pregnancy BMI, ethnicity, parity, education, height, smoking and cohort (not
shown).єAdjusted for age, pre-pregnancy BMI, ethnicity and cohort (not shown)
Abbrevations: aOR adjusted odds ratio, CI confidens interval, BMI body mass index
* Not measured in Fit for Delivery
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European background, n = 2588
BMI≥ 25 kg/m2 53.0 75.6 15.5 95 26.6 47.0
BMI≥ 27 kg/m2 36.6 87 19.2 94.2 14.9 63.4
BMI≥ 30 kg/m2 22.8 94.4 24.4 93.9 6.8 77.7
Age≥ 25 years 91.1 10.1 7.9 93.1 90.0 8.9
Age≥ 30 years 60.4 45.5 8.6 93.1 54.9 39.6
Age≥ 25 or BMI≥ 25 96.5 7.2 8.1 96.1 93.1 3.5
Age≥ 30 or BMI≥ 30 71.3 42.7 9.5 94.6 58.4 28.7
Age≥ 30 or BMI≥ 27 74.3 39.4 9.4 94.8 61.6 25.7
BMI≥ 25 or (Primipara + Age ≥ 25) or (parous +
age ≥ 35)
85.1 26.0 8.9 95.4 74.9 14.9
BMI≥ 25 or (Primipara + Age ≥ 25) or (parous +
age ≥ 40)
78.7 32.3 9.0 94.7 68.5 21.3
BMI≥ 25 or (Primipara + Age ≥ 30) or (parous +
age ≥ 35)
72.8 47.9 10.6 95.4 53.7 27.2
BMI≥ 27 or (Primipara + Age ≥ 30) or (parous +
age ≥ 35)
61.9 54.5 10.3 94.4 46.8 38.1
Family history of diabetes* 11.5 89.1 8.7 92.1 10.6 87.3
BMI≥ 25 or Age≥ 30 or family history of diabetes 87.8 22.8 9.3 95.4 78.1 12.2
Non-European background, n = 393
BMI≥ 23 kg/m2 64.2 46.0 30.5 77.6 56.7 35.8
BMI≥ 25 kg/m2 47.2 66.2 34.0 77.2 37.4 52.8
BMI≥ 27 kg/m2 37.7 80.5 41.7 77.8 24.4 62.3
Age≥ 25 years 80.2 23.3 27.9 76.1 77.6 19.8
Age≥ 30 years 50.0 63.4 33.5 77.4 40.2 50.0
Age≥ 25 or BMI≥ 25 87.7 17.4 28.2 79.4 84.0 12.3
Age≥ 30 or BMI≥ 23 74.5 33.1 29.2 77.9 69.0 25.5
BMI≥ 25 or (Primipara + Age ≥ 25) or (parous +
age ≥ 35)
69.8 42.5 31.0 79.2 60.8 30.2














European background, n = 2588
BMI≥ 25 kg/m2 48.3 76.8 25.0 90.3 26.6 51.7
BMI≥ 27 kg/m2 33.2 87.9 29.5 89.7 14.9 66.8
BMI≥ 30 kg/m2 16.6 94.8 33.7 87.7 6.8 83.4
Age≥ 25 years 90.4 10.1 13.8 86.9 90.0 9.6
Age≥ 30 years 62.1 46.2 15.5 88.4 54.9 37.9
Age≥ 25 or BMI≥ 25 95.2 7.2 14.1 90.4 93.1 4.8
Age≥ 30 or BMI≥ 30 69.7 43.4 16.4 90.0 58.4 30.3
Age≥ 30 or BMI≥ 27 75.0 40.5 16.7 91.0 61.6 25.0
BMI≥ 25 or (Primipara + Age ≥ 25) or (parous +
age ≥ 35)
83.1 26.4 15.3 90.8 74.9 16.9
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differs somewhat in terms of inclusion period, time
of OGTT and geography, although by including Nor-
wegian studies only and adjusting for study cohort
this source of heterogeneity was limited.
Conclusion
The use of a stricter diagnostic criteria than the
2013WHO (OR of 2.0 vs. 1.75) limited the prevalence
of GDM to approximately the same level as the
older 1999WHO. We found that maternal characteris-
tics are of limited use in identifying women with
GDM, requiring testing of almost all women to avoid
overlooking a substantial number of cases. The costs
and benefits of universal screening, and the use of
alternative testing algorithms or biomarkers, require
further evaluation.
Table 5 Performance of risk factors, alone or in combination, for the identification of GDM, with two criteria (2017 Norwegian and
2013 WHO) (Continued)
BMI≥ 25 or (Primipara + Age ≥ 25) or (parous +
age ≥ 40)
76.4 32.7 15.3 89.7 68.5 23.6
BMI≥ 25 or (Primipara + Age ≥ 30) or (parous +
age ≥ 35)
71.1 49.1 18.2 91.4 53.7 28.9
BMI≥ 27 or (Primipara + Age ≥ 30) or (parous +
age ≥ 35)
62.9 55.8 18.5 90.4 46.8 37.1
Family history of diabetes* 13.2 89.5 17.3 86.6 10.6 86.8
BMI≥ 25 or Age≥ 30 or family history of diabetes 87.5 23.5 16.2 91.8 78.1 12.5
Non-European background, n = 393
BMI≥ 23 kg/m2 66.2 49.0 43.9 70.6 56.7 33.8
BMI≥ 25 kg/m2 47.3 68.6 47.6 68.3 37.4 52.7
BMI≥ 27 kg/m2 36.5 89.2 56.3 68.4 24.4 63.5
Age≥ 25 years 80.4 24.1 39.0 67.0 77.6 19.6
Age≥ 30 years 48.0 64.5 44.9 67.2 40.2 52.0
Age≥ 25 or BMI≥ 25 87.8 18.4 39.4 71.4 84.0 12.2
Age≥ 30 or BMI≥ 23 76.4 35.5 41.7 71.3 69.0 23.6
BMI≥ 25 or (Primipara + Age ≥ 25) or (parous +
age ≥ 35)
69.6 44.5 43.1 70.8 60.8 30.4
Family history of diabetes* 40.1 64.0 40.1 64.0 37.6 59.9
Abbrevations: BMI body mass index, WHO World Health Organization, PPV positive predictive value, NPV negative predictive value, OGTT oral glucose tolerance
test, GDM gestational diabetes
*Family history of diabetes was not measured in Fit for Delivery
Fig. 3 Screening performance (sensitivity and percentage offered an OGTT) of risk factors (single or in combinations) for European women with
the 2017Norwegian criteria (a) and 2013WHO criteria (b). The color of the points indicates the risk factors used, and the line indicates 80%
sensitivity. The clusters indicate poor (bottom left corner), moderate and good performance (top right corner)
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